化疗联合恩度治疗非小细胞肺癌临床观察  

作　　者：朱小生[1] 胡晓文[1] 操乐杰[1] 高圣堂[1] 徐飞[1] 夏淮玲[1] 

机构地区：[1]安徽医科大学附属省立医院呼吸科,合肥230001

出　　处：《临床肺科杂志》2009年第2期194-195,共2页Journal of Clinical Pulmonary Medicine

基　　金：安徽省2008年科技计划项目资助(编号08020303088)

摘　　要：目的探讨恩度联合化疗的疗效、毒副作用及生存率影响。方法采用标准肺癌化疗方案(GP/NP)联合恩度15mg/天,观察2个以上疗程治疗后疗效并随访。结果恩度联合化疗有效率(CR+PR)达46.2%,明显优于单纯化疗,而毒副作用轻微。结论恩度联合化疗能增加疗效,毒副作用可以耐受,值得临床推广。Objective To evaluate the efficacy , safety and survival rate of EndostarTM （YH-16） combined with chemotherapy for non-small cell lung cancer （NSCLC）. Methods The patients were treated with more than 2 cycles of standard chemotherapy regimen （GP/NP） combined with YH-16 （15 mg/d）. The efficacy was observed and the patients were follow-up visited. Results The response rate （ CR ＋ PR） of the treatment group obviously surpassed the control group （48. 1% versus 14. 3 % , P 〈 0. 005 ）, and the toxicity was little. Conclusion Significant efficacy and safety against NSCLC were observed in YH-16 in combination with chemotherapy compared with chemotherapy alone. It is worthy of extensive clinical application.

关 键 词：化疗 恩度 肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R285.1[医药卫生—临床医学]